Akari Therapeutics (AKTX)
NASDAQ:AKTX
Want to see AKTX full AI Analyst Report?
Top Page
Akari Therapeutics
(NASDAQ:AKTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$12.00
▲(4185.71% Upside)
Action:Reiterated
Date:06/19/26
The score is primarily held down by weak financial performance (no revenue, recurring losses, and ongoing cash burn that implies continued financing risk), partially offset by low leverage. Technicals are mixed with neutral momentum, offering limited support, while valuation metrics provide little help due to negative earnings and no dividend yield data.
Positive Factors
Low financial leverage
The company’s minimal debt load is a durable structural strength: low leverage reduces near-term refinancing risk and interest burden, preserving optionality to fund clinical programs through equity or partnerships. This conserves cash flexibility over the next several quarters.
Negative Factors
No revenue / persistent losses
A pre-commercial biotech model with sustained large operating losses is a long-term structural weakness: without product revenue the firm must rely on external funding or partnerships. Persistent losses erode resources and make long-term viability contingent on successful trials or continued financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
The company’s minimal debt load is a durable structural strength: low leverage reduces near-term refinancing risk and interest burden, preserving optionality to fund clinical programs through equity or partnerships. This conserves cash flexibility over the next several quarters.
Read all positive factors
Akari Therapeutics (AKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.52M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$27.00Price Target Upside9542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.89
Revenue Forecast (FY)N/A
Akari Therapeutics Business Overview & Revenue Model
Company Description
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement...
How the Company Makes Money
null...
Akari Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.35M | -19.53M | -10.00M | -17.74M | -17.42M |
| Net Income | -17.30M | -19.79M | -10.01M | -17.75M | -17.42M |
Balance Sheet | |||||
| Total Assets | 47.89M | 50.56M | 4.36M | 13.83M | 11.65M |
| Cash, Cash Equivalents and Short-Term Investments | 5.20M | 2.60M | 3.85M | 13.25M | 9.36M |
| Total Debt | 754.00K | 3.26M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 19.56M | 28.33M | 4.58M | 12.04M | 6.09M |
| Stockholders Equity | 28.33M | 22.23M | -229.00K | 1.79M | 5.55M |
Cash Flow | |||||
| Free Cash Flow | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Operating Cash Flow | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Investing Cash Flow | 0.00 | 382.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 13.17M | 10.99M | 7.02M | 25.29M | 14.29M |
Akari Therapeutics Technical Analysis
Negative
0.28
Price Trends
8.81
Positive
8.54
Positive
15.99
Negative
Market Momentum
1.05
Positive
46.50
Neutral
5.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 14.60, below the 50-day MA of 8.81, and below the 200-day MA of 15.99, indicating a neutral trend. The MACD of 1.05 indicates Positive momentum. The RSI at 46.50 is Neutral, neither overbought nor oversold. The STOCH value of 5.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.
Akari Therapeutics Risk Analysis
Akari Therapeutics disclosed 53 risk factors in its most recent earnings report. Akari Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Akari Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $305.86M | -537.70 | -0.29% | ― | -100.00% | 72.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $12.52M | >-0.01 | -68.21% | ― | ― | ― | |
45 Neutral | $32.18M | -3.74 | -92.69% | ― | ― | 37.68% | |
44 Neutral | $15.37M | -0.39 | ― | ― | ― | 80.65% | |
42 Neutral | $17.93M | -0.48 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
AKTX
Akari Therapeutics
10.94
-35.46
-76.42%
NNVC
NanoViricides
1.40
0.03
2.19%
MBRX
Moleculin Biotech
2.88
-3.97
-57.94%
PASG
Passage Bio
5.59
-1.11
-16.57%
SABS
SAB Biotherapeutics
4.00
2.24
127.27%
Akari Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Akari Therapeutics Announces Private Placement of Equity Securities
Neutral
May 22, 2026
On May 20, 2026, Akari Therapeutics entered into a securities purchase agreement with certain investors for a private placement of 1,470,588 unregistered American Depositary Shares, or pre-funded warrants in lieu of ADSs, bundled with Series H, I ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.